HGFK1 inhibits the self-renewal ability and CDDP-induced chemo-resistance of CD90+ CSCs via the in vitro inhibition of the Wnt/β-catenin and Notch pathways and, consecutively, the in vitro downregulation of HGF/Met expression in HCC. Here, MET is linked to hepatocellular carcinoma.